Biogen's Alzheimer's Drug Sharply Slows Cognitive Decline

The FDA approved selumetinib for adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas based on the KOMET trial.

On this episode of Managed Care Cast, we're talking with the chief science officer of the Center for Innovation & Value Research about key insights from its Rare Disease project.

David Mitchell, PharmD, MBA, UC Davis, shares how collaboration between health systems and manufacturers is transforming patient access and outcomes for rare disease treatments.

Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.

David Mitchell, PharmD, MBA, senior pharmacist manager and assistant clinical professor at UC Davis, addresses how health systems are overcoming financial, operational, and access challenges for patients with rare diseases.

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.